The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection

Inclusion Criteria: * Aged ≥18 years (inclusive of the boundary value), with no restriction on gender. * Expected survival time of at least 3 months. * Subjects with refractory moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options. * Meet the requirements for liver and kidney function, as well as cardiopulmonary function. * Free from severe psychiatric disorders. * Able to understand the trial and have signed the informed consent form. Exclusion Criteria: * A history of malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years prior to screening. * Subjects with positive results in virus/syphilis tests. * Severe cardiac diseases or unstable systemic diseases. * Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening. * Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion. * Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening. * Subjects who participated in other clinical studies within 1 month before screening. * Other conditions deemed unsuitable for enrollment by the investigator.